Table 3 Results of the effectiveness indicators evaluated in the study
Variables (n = 53 sessions) | Measurements |
|---|---|
Pause of Therapy, n (%) | 12 (22.6) |
Reason for the pause | |
Hemodynamic instability, n (%) | 2 (3.7)* |
Catheter thrombosis, n (%) | 1 (1.9) |
System coagulation, n (%) | 9 (17.3) |
Prescribed time (hours), median (IQR) | 12.32 (8-15) |
Run time (hours), median (IQR) | 10.5 (6-12) |
Total of sessions, n | 53 |
Completeness of prescribed time | |
100-80%, n (%) | 40 (75.5) |
79-70%, n (%) | 1 (1.89) |
69-60%, n (%) | 2 (3.77) |
< 60%, n (%) | 10 (18.9) |
COVID-19 patients, n | 29 |
Completeness of prescribed time | |
100-80%, n (%) | 22 (75.9) |
79-70%, n (%) | 1 (3.4) |
69-60%, n (%) | 1 (3.4) |
< 60%, n (%) | 5 (17.2) |
COVID-19 patients with VAD, n | 20 |
Completeness of prescribed time | |
100-80%, n (%) | 15 (75) |
79-70%, n (%) | 1 (5) |
69-60%, n | 0 |
< 60%, n (%) | 4 (20) |